Expression and biological function of ADAM28 in colorectal adenocarcinoma

Takuya Hattori1, Naoya Sakamoto1, Koh Hori3, Masayuki Shimoda2, Akira Ishikawa2, Daiki Taniyama2, Rinoro Homo1, Naohide Oue1, Kazuhiro Sentani1, Takao Hinoi2, Hiroiyuki Ugi1, Hideki Ohdan3, Yasunori Okada4, Wataru Yasui5

INTRODUCTION

In our previous study, we examined expression of differentiation and molecular markers that are most likely to be involved in serrated tumor development, and revealed concurrent Cdx2 inactivation and BRAF expression promotes serrated invasive tumor in mice. We decided to focus on ADAM28 as candidate because ADAM20 was upregulated in this tumor and TCGA data that had low CDX2 and Braf expression promotes colorectal cancer progression.

METHODS

Correlation between ADAM28s expression and clinicopathological features

ADAM28 expression was observed frequently in Pathological T3/4 grade cases. A Cox proportional hazard model (univariate and multivariate analyzes) was used to analyze correlations between ADAM28 expression and clinical features.

RESULTS

ADAM28 expression was an independent poor prognosis factor.

Conclusion

ADAM28 and ADAM28 could be promising candidates of a diagnostic marker for serrated CRC and a therapeutic target for CRC.

We are now searching the details of molecular machinery that ADAM28 directly works on.

REFERENCES

1 Department of Molecular Pathology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
2 Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
3 Department of Surgery, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
4 Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
5 Department of Pathophysiology for Locomotive and Neoplastic Diseases, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Takuyu Hattori

Department of Molecular Pathology

Department of Molecular Pathology

1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan

E-mail: ohatahattori47@gmail.com

Phone: 81-082-255-5147, Fax: 81-082-257-5149

Web: http://home.hiroshima-u.ac.jp/kyo1/